Skip to main content

Table 4 Maximum severity of ARD corresponding to the RTOG/EORTC score in included patients during the study follow-up visits1

From: Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial

ARD severity

Timolol

Placebo

Overall P-Value

N (%)

0

1 (3.1%)

0 (0.0%)

0.002

I

21 (65.6%)

8 (25.0%)

 

II

10 (31.3%)

24 (75.0%)

 

III

0 (0.0%)

(12.5)

 
  1. N Number, ARD Acute radiation dermatitis
  2. 1Follow up is referred to “within 2 weeks after the completion ofof ending the radiation therapy”
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us